The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
Open Access
- 1 July 2021
- journal article
- research article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 27 (3), 474-485
- https://doi.org/10.3350/cmh.2021.0015
Abstract
Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on disease severity is commonly practiced, the efficacy of such approach remained uncertain. We aimed to compare the impact of unrestricted access to direct-acting antiviral (DAA) among incarcerated HCV-infected patients in Singapore. Methods: In this retrospective study, we reviewed all incarcerated HCV-infected patients treated in our hospital during the restricted DAA era (2013-2018) and unrestricted DAA access era (2019). Study outcomes included the rate of sustained virological response (SVR), treatment completion and treatment default. Subgroup analysis was performed based on the presence of liver cirrhosis, HCV genotype and HCV treatment types. Results: A total of 1,001 HCV patients was followed-up for 1,489 person-year. They were predominantly male (93%) with genotype-3 HCV infection (71%), and 38% were cirrhotic. The overall SVR during the restricted DAA access era and unrestricted DAA access era were 92.1% and 99.1%, respectively. Unrestricted access to DAA exponentially improved the treatment access among HCV-infected patients by 460%, resulting in a higher SVR rate (99% vs. 92%, P=0.003), higher treatment completion rate (99% vs. 93%, P<0.001) and lower treatment default rate (1% vs. 9%, P<0.001). Conclusion: In this large cohort of incarcerated HCV-infected patients, we demonstrated that unrestricted access to DAA is an impactful strategy to allow rapid treatment up-scale in HCV micro-elimination.Keywords
This publication has 45 references indexed in Scilit:
- HCV infected prisoners: should they be still considered a difficult to treat population?BMC Infectious Diseases, 2013
- Absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV‐infected, evaluated patientsAlimentary Pharmacology & Therapeutics, 2013
- Comparison of hepatitis C virus treatment between incarcerated and community patientsHepatology, 2012
- High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis CJournal of Gastroenterology and Hepatology, 2010
- Treatment Outcomes With Pegylated Interferon and Ribavirin for Male Prisoners With Chronic Hepatitis CJournal of Clinical Gastroenterology, 2009
- Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment PopulationsClinical Infectious Diseases, 2008
- Access to Treatment of Hepatitis C in Prison InmatesDigestive Diseases and Sciences, 2008
- Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison PopulationAmerican Journal of Public Health, 2005
- Hepatitis C Virus Infection among Prisoners in the California State Correctional SystemClinical Infectious Diseases, 2005
- Treatment of Chronic Hepatitis C in a State Correctional FacilityAnnals of Internal Medicine, 2003